The most recent quarter marked the worst first quarter on record for both the S&P 500 and the Dow Jones. For investors in search of a bright spot, investing firm Morgan Stanley sees plenty of compelling opportunities being presented as a result of the market’s COVID-19-driven sell-off. Morgan Stanley's chief U.S. equity strategist Mike Wilson stated, “We like these prices a lot.” He added, “We’ve been scaling back into stocks over the last two, three or four weeks...We think this is probably the best risk-reward we’ve seen for investors in two years.”Heeding Wilson’s advice, we used TipRanks’ database to take a closer look at stocks covered by Morgan Stanley’s analysts in the hope of finding some exciting plays to catch on recent weakness. It turns out that two of the firm’s recently upgraded picks have received significant support from other members of the Street, with the Buy-rated tickers also offering some...
(Bloomberg) -- Tesla Inc. tends to pull out all the stops at the end of each quarter, with Chief Executive Officer Elon Musk often rallying the troops to deliver as many vehicles as possible to customers.This approach probably didn’t work well for Tesla in March, with shelter-in-place orders and distancing guidelines around the globe limiting how many vehicles the company could hand over. While Musk tried to salvage the quarter by introducing a “touchless” delivery option in select locations, the coronavirus pandemic is expected to have done a number on demand for all automakers.Analysts on average estimate Tesla delivered roughly 78,100 cars worldwide last quarter -- the first to include hand-overs of the new Model Y crossover. While that would be a jump from a disappointing result a year ago, it also would mark a more than 30% drop from the record deliveries Tesla reported for the last three months of...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) * Athersys Inc (NASDAQ: ATHX) * Forty Seven Inc (NASDAQ: FTSV) * Ra Pharmaceuticals Inc (NASDAQ: RARX) * Quidel Corporation (NASDAQ: QDEL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 31) * Aikido Pharma Inc (NASDAQ: AIKI) * BIOLASE Inc (NASDAQ: BIOL) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) * Gritstone Oncology Inc (NASDAQ: GRTS) * Neovasc Inc (NASDAQ: NVCN)(moved in reaction to its fourth quarter results) * Opko Health Inc. (NASDAQ: OPK) * Phio Pharmaceuticals Corp (NASDAQ: PHIO)(announced $4 million registered offering) * Second Sight Medical Products Inc (NASDAQ: EYES)Related Link: Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning JudgmentStocks In Focus Inflarx Begins Human Testing Of Lead Drug For COVID-19-induced Pneumonia German biopharma Inflarx NV (NASDAQ: IFRX) said it has enrolled...
It’s 2008 all over again, only much worse. And just like back then, PMs are likely to slide very fast, very far and then recover in a big way. A lot of money is likely to be made by those, who are positioned correctly....
